Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PLRX POWR Grades
- PLRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 74.67% of US stocks.
- PLRX's strongest trending metric is Value; it's been moving down over the last 179 days.
- PLRX's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).
PLRX Stock Summary
- Pliant Therapeutics Inc's stock had its IPO on June 3, 2020, making it an older stock than merely 4.63% of US equities in our set.
- With a price/sales ratio of 36.72, Pliant Therapeutics Inc has a higher such ratio than 95.19% of stocks in our set.
- Revenue growth over the past 12 months for Pliant Therapeutics Inc comes in at -81.89%, a number that bests only 1.35% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Pliant Therapeutics Inc are GLYC, IDYA, JNCE, WVE, and MEIP.
- Visit PLRX's SEC page to see the company's official filings. To visit the company's web site, go to pliantrx.com.
PLRX Valuation Summary
- In comparison to the median Healthcare stock, PLRX's price/sales ratio is 1202.63% higher, now standing at 49.5.
- Over the past 15 months, PLRX's price/sales ratio has gone up 36.7.
- Over the past 15 months, PLRX's EV/EBIT ratio has gone up 968.6.
Below are key valuation metrics over time for PLRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PLRX | 2021-08-31 | 49.5 | 2.7 | -8.1 | -7.6 |
| PLRX | 2021-08-30 | 48.4 | 2.6 | -7.9 | -7.5 |
| PLRX | 2021-08-27 | 48.8 | 2.6 | -7.9 | -7.5 |
| PLRX | 2021-08-26 | 48.9 | 2.7 | -8.0 | -7.5 |
| PLRX | 2021-08-25 | 49.6 | 2.7 | -8.1 | -7.7 |
| PLRX | 2021-08-24 | 49.7 | 2.7 | -8.1 | -7.7 |
PLRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PLRX has a Quality Grade of D, ranking ahead of 14.66% of graded US stocks.
- PLRX's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PLRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.047 | 1 | -0.360 |
| 2021-03-31 | 0.050 | 1 | -0.363 |
| 2020-12-31 | 0.149 | 1 | -0.245 |
PLRX Price Target
For more insight on analysts targets of PLRX, see our PLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.33 | Average Broker Recommendation | 1.38 (Strong Buy) |
PLRX Stock Price Chart Interactive Chart >
PLRX Price/Volume Stats
| Current price | $4.92 | 52-week high | $33.95 |
| Prev. close | $4.37 | 52-week low | $3.96 |
| Day low | $4.43 | Volume | 540,800 |
| Day high | $5.07 | Avg. volume | 156,423 |
| 50-day MA | $6.99 | Dividend yield | N/A |
| 200-day MA | $13.41 | Market Cap | 177.95M |
Pliant Therapeutics Inc. (PLRX) Company Bio
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Latest PLRX News From Around the Web
Below are the latest news stories about Pliant Therapeutics Inc that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
Pliant gets safety review nod to advance phase 2a trial of lung therapy at higher dosePliant Therapeutics (NASDAQ:PLRX) said that following a positive independent safety review, enrollment has begun in a phase 2a trial of PLN-74809 at 320 mg dose in patients with idiopathic pulmonary fibrosis (IPF), a type of lung disease. The independent Data Safety Monitoring Board review recommended the phase 2a trial, dubbed INTEGRIS-IPF, continue... |
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary FibrosisRecent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg Trial initiation follows the FDA authorization of evaluation of long-term dosing of PLN-74809 at doses up to 320 mg in IPF patients SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel |
Pliant Therapeutics (NASDAQ:PLRX) investors are sitting on a loss of 69% if they invested a year agoEven the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Pliant Therapeutics... |
H.C. Wainwright Thinks Pliant Therapeutics’ Stock is Going to RecoverE…. |
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 MilestonesEnrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022 FDA has authorized evaluation of long-term treatment with PLN-74809 at doses up to 320 mg in IPF Company will present updates at the 40th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of |
PLRX Price Returns
| 1-mo | N/A |
| 3-mo | -57.44% |
| 6-mo | -69.82% |
| 1-year | -82.46% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -63.56% |
| 2021 | -40.58% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...